Picture loading failed.

Anti-ITGA4_ITGB7&ITGAE_ITGB7 therapeutic antibody (Pre-made Etrolizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Etrolizumab (rhuMAb Beta7) is a biopharmaceutical drug candidate being developed for the treatment of ulcerative colitis and Crohn's disease. It is a humanized monoclonal antibody against the β7 subunit of integrins α4β7 and αEβ7. Etrolizumab was developed by Genentech by engineering the FIB504 antibody to include human IgGl-heavy chain and κ-light chain frameworks; it is manufactured in CHO cells.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-200-1mg 1mg 3090
GMP-Bios-ab-200-10mg 10mg 21890
GMP-Bios-ab-200-100mg 100mg 148000
GMP-Bios-ab-200-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-ITGA4_ITGB7&ITGAE_ITGB7 therapeutic antibody (Pre-made Etrolizumab biosimilar,Whole mAb)
INN Name Etrolizumab
TargetITGA4_ITGB7&ITGAE_ITGB7
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2010
Year Recommended2011
CompaniesGenentech;Roche
Conditions Approvedna
Conditions ActiveCrohn's disease;Ulcerative colitis
Conditions Discontinuedna
Development Techna